KORU Medical Swings to Q2 Profit, Raises Gross Margin Outlook
KRMD sits 22% above its 52-week low of $3.2.
Summary
KORU Medical posted Q2 revenue of $12M, up 18% YoY, and swung to a net profit of $0.25M from a loss last year. Gross margin hit 65.1%, driven by lower manufacturing costs and higher average selling prices. Management narrowed full-year revenue guidance to $47.5-$48.5M and raised gross margin outlook to 62%-64%, signaling confidence in sustained profitability. The company also acquired a connected monitoring technology asset to enhance its platform. This follows a strong Q1 and a recently amended supply agreement extending to 2031, reinforcing the turnaround narrative. The stock closed at $4.24 on Aug 4, well below the $7.00 median analyst target.
At the time of this announcement, KRMD was trading at $3.90 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $189.7M. The 52-week trading range was $3.20 to $6.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.